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Abstract: Incidences and morphological features of thyroid proliferative lesions induced by carcinogens in Wistar Hannover GALAS 
rats (GALAS rats) showing normal growth with or without thyroid dysplasia were examined. All thyroid tissue samples were obtained 
from our recently conducted study using male GALAS rats treated with 5 carcinogens according to the medium-term multiorgan car-
cinogenicity bioassay protocol (called DMBDD treatment). In the DMBDD-treated rats, thyroid dysplasia was found in 9 out of 114 
rats. Follicular cell adenomas were found in 5 out of 9 rats with thyroid dysplasia and in 7 out of 105 rats without thyroid dysplasia. 
The incidence of adenoma was significantly increased in rats with thyroid dysplasia (55.6%) compared with that in rats without thyroid 
dysplasia (6.7%). Adenomas in rats with thyroid dysplasia were observed as single or multiple nodules, well demarcated and composed 
of variously sized vacuolated cells or unvacuolated cells. These histopathological features and staining profiles of luminal colloid for 
PAS and thyroglobulin, together with PCNA-positive cells, were fundamentally similar to those of rats without thyroid dysplasia. On 
the other hand, the luminal colloid in adenomas of rats with thyroid dysplasia had a tendency to be poorly stained for T4 compared 
with that of rats without thyroid dysplasia. From these findings, it appears that dysplastic thyroids of rats showing normal growth are 
more sensitive to carcinogens than normal thyroids. In addition, the morphological features of carcinogen-induced thyroid prolifera-
tive lesions in GALAS rats with thyroid dysplasia were fundamentally similar to those of rats without thyroid dysplasia, except for the 
vacuoles and T4 staining profile. (DOI: 10.1293/tox.25.11; J Toxicol Pathol 2012; 25: 11–17)
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Introduction
Wistar Hannover GALAS rats (GALAS rats) have 
recently been used in toxicity studies in Japan because of 
their beneficial characteristics such as a higher survival rate 
and a lower body weight than other ordinary strains, such 
as Sprague-Dawley and Fisher 3441. In GALAS rats, it has 
been reported that vacuolar change of thyroid follicular cells 
sometimes occurs as a spontaneous lesion2. Histopathologi-
cally, this lesion is characterized by huge vacuoles in the 
follicular cells, which are distributed diffusely within the 
thyroid2. The vacuole formation is attributed to the dilation 
of rough endoplasmic reticula (r-ERs) that are present at the 
basal site of the follicular cells2. The vacuolar change of thy-
roid follicular cells has been called ‘thyroid dysplasia’3 and 
confirmed as an autosomal recessive hereditary disorder3,4. 
Homozygous animals with thyroid dysplasia exhibit dwarf-
ism due to hypothyroidism. These thyroids show little col-
loid formation and decreased follicular size, and the serum 
values of growth hormone (GH), triiodothyronine (T3) and 
thyroxine (T4) are markedly low in the dwarf rats3,4. On the 
other hand, heterozygous animals exhibit thyroid dysplasia 
without external abnormality or endocrinological derange-
ment2–4. There are several reports regarding spontaneous 
thyroid proliferative lesions in GALAS rats showing normal 
growth with thyroid dysplasia3 and in dwarfs5. However, 
few reports have been published that deal with chemical-
induced thyroid proliferative lesions in these rats.
We observed the development of thyroid proliferative 
lesions in male GALAS rats showing normal growth with 
thyroid dysplasia in a recently conducted study6. That study 
was based on the medium-term multiorgan carcinogenicity 
bioassay protocol featuring a combined treatment with 5 
chemical carcinogens7–9. In the present study, we evaluated 
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the incidences of carcinogen-induced thyroid proliferative 
lesions in GALAS rats with or without thyroid dysplasia, and 
examined the histopathological, histochemical and immuno-
histochemical features of these thyroid proliferative lesions.
Materials and Methods
Thyroid tissue samples
All thyroid tissue samples were obtained from our 
recently conducted medium-term multiorgan carcino-
genicity bioassay using male Wistar Hannover GALAS 
(BrlHan:WIST@Jcl, GALAS) rats with an externally nor-
mal appearence6. Briefly, 6-week-old rats provided by CLEA 
Japan, Inc. (Tokyo, Japan) were subjected to a combined 
treatment with 5 carcinogens targeting different organs (the 
DMBDD treatment: a single intraperitoneal administration 
of 100 mg/kg body weight of N-nitrosodiethylamine at com-
mencement, 4 intraperitoneal administrations of 20 mg/kg 
body weight each of N-methylnitrosourea during the first 2 
weeks, 4 subcutaneous administrations of 40 mg/kg body 
weight each of 1,2-dimethylhydrazine during the second 2 
weeks and continuous administrations by admixing into the 
drinking water N-butyl-N-(4-hydroxybutyl)nitrosamine at 
a concentration of 0.05% for the first 2 weeks and 2,2’-di-
hydroxy-di-n-propylnitrosamine at a concentration of 0.1% 
for the second 2 weeks) or their vehicles during the initial 
4-week period. Subsequently, all rats were given a basal 
diet or a diet containing test substances (copper gluconate 
and green tea catechins) for 25 weeks and then sacrificed 
under light ether anesthesia to obtain major organs/tissues 
including the thyroids. These were fixed in a 10% neutrally 
buffered formalin solution, embedded in paraffin and sec-
tioned to prepare 4-μm-thick specimens. Because none of 
the used test substances alone exerted carcinogenic or toxi-
cological effects on the thyroid in the rats with or without 
the DMBDD treatment, we considered that there was no ef-
fect of the test substance treatment on the thyroids and han-
dled the DMBDD-treated rats as a one group in this study. 
As a result, thyroid tissue samples were available from 114 
DMBDD-treated rats. These experiments were conducted 
according to the Guidelines for Animal Experimentation, 
Japanese Association for Laboratory Animal Science, 1987.
Histological, histochemical and immunohistochemical 
examinations
Histological examination was performed on the thyroid 
specimens processed by a routine hematoxylin and eosin 
(H.E.) staining procedure. We diagnosed the thyroid pro-
liferative lesions according to the criteria of Boorman and 
Elvell10 and counted their numbers from bilateral thyroid 
glands on one section. The thyroid specimens for which pro-
liferative lesions were observed were sectioned additionally 
and used for the following examinations. For histochemical 
examination, the specimens were processed for the periodic 
acid-Schiff (PAS) reaction. For immunohistochemical ex-
aminations, the specimens were stained for thyroglobulin 
(polyclonal antibody, Dako Japan Inc., Kyoto, Japan; 100-
fold dilution), L-thyroxine (T4) (polyclonal antibody, Sigma-
Aldrich, Inc., St. Louis, MO, USA; 100-fold dilution) and 
calcitonin  (polyclonal  antibody,  Dako;  100-fold  dilution) 
using  a  labeled  polymer  method  (Histofine  Simple  Stain 
Rat MAX-PO (MULTI), Nichirei Biosciences Inc., Tokyo, 
Japan) and for proliferating cell nuclear antigen (PCNA) 
(monoclonal antibody, clone PC10, Dako; 50-fold dilution) 
using an avidin-biotin complex method (Vectastain ABC 
Kit, Vector Laboratories Inc., Burlingame, CA, USA).
Statistics
Fisher’s exact test was performed for intergroup differ-
ences of lesion incidences between rats with thyroid dyspla-
sia and rats without thyroid dysplasia. For intergroup dif-
ferences of lesion multiplicities, the F-test was performed, 
followed by the Aspin-Welch test when there was a signifi-
cant difference or by the Student’s t-test when there was no 
significant difference. The level of significance was set at P 
< 0.05.
Results
The incidences of thyroid dysplasia and proliferative 
lesions in the DMBDD-treated rats are listed in Table 1. 
Thyroid dysplasia was found in 9 out of 114 rats. Follicular 
cell hyperplasia was found in 1 out of 9 rats with thyroid 
dysplasia and 6 out of 105 rats without thyroid dysplasia. 
There was no significant difference in the incidence of hy-
perplasia in rats with thyroid dysplasia (11.1%) compared 
with that of rats without thyroid dysplasia (5.7%). Follicular 
cell adenomas were found in 5 out of 9 rats with thyroid 
dysplasia and 7 out of 105 rats without thyroid dysplasia. 
The incidence of adenoma was significantly increased in 
rats with thyroid dysplasia (55.6%) compared with that of 
rats without thyroid dysplasia (6.7%). There was no signifi-
cant difference in the multiplicity of adenoma in rats with 
thyroid dysplasia (4.4 ± 5.5/rat) compared with that of rats 
without thyroid dysplasia (1.4 ± 0.79/rat).
Histopathologically, follicular cell hyperplasia, which 
was detected in one rat with thyroid dysplasia, was observed 
as one small proliferative follicle lined by a single layer of 
epithelium with small vacuoles that partly formed a short 
papillary projection into the lumen (Figs. 1A and B). Fol-
licular cell adenomas of rats with thyroid dysplasia were ob-
served as single or multiple nodules in unilateral or bilateral 
thyroid glands. They were well demarcated, slightly com-
pressed their adjacent tissue and lacked a capsule (Fig. 2A). 
These follicles were filled with colloid, but one adenoma 
lacked luminal colloid, and the follicles contained eosino-
philic debris (Fig. 2A, nodule i). Adenomas were composed 
of follicles with various sizes and were principally lined by 
a single layer of epithelial cells (Fig. 2A, nodules f, g, h and 
i). Occasionally, they formed irregular papillary projections 
into the lumen (Fig. 2B, high magnification of nodule h). The 
follicular cells of adenomas showed several different charac-
teristics such as a high columnar epithelium with huge vacu-
oles (Fig. 2C lower half, high magnification of nodule f), a Abe, Hayashi, Usuda et al. 13
low columnar epithelium with small vacuoles (Fig. 2D, high 
magnification of nodule g) and a basophilic epithelium with-
out vacuoles (Fig. 2C upper half, high magnification of nod-
ule h). All adenomas in rats with thyroid dysplasia showed a 
low degree of cellular atypia and no invasion or metastasis 
regardless of being composed of vacuolated or unvacuolated 
cells. In addition, the histopathological features of hyperpla-
sias and adenomas of rats with thyroid dysplasia were fun-
damentally similar to those of rats without thyroid dysplasia 
except for the vacuoles.
The staining properties for follicular cell adenomas in 
the DMBDD-treated rats with or without thyroid dysplasia 
are listed in Table 2. The staining profiles of luminal colloid 
for PAS (Fig. 3A) and thyroglobulin (Fig. 3B), together with 
PCNA-positive cells in adenomas seen in rats with thyroid 
dysplasia, were fundamentally close to those of the coun-
terparts seen in rats without thyroid dysplasia (Table 2). On 
the other hand, the luminal colloid of all adenomas in rats 
without thyroid dysplasia was minimally or slightly positive 
for T4, while about one-quarter of that in rats with thyroid 
dysplasia were negative for T4 (Fig. 3C and Table 2). The 
luminal colloid of surrounding follicular cells in rats with 
or without thyroid dysplasia was slightly positive for PAS, 
thyroglobulin and T4. In addition, the luminal colloid of a 
carcinoma in a rat without thyroid dysplasia was moder-
ately positive for PAS but negative for thyroglobulin and T4, 
and the PCNA-positive cells were detected moderately. The 
materials of intracellular vacuoles were negative for PAS, 
thyroglobulin and T4 in follicular cells regardless of hyper-
plasia, adenoma or their surrounding follicular cells in rats 
with thyroid dysplasia. All proliferative lesions in the thy-
roids examined in this study were negative for calcitonin, 
while C-cells in the adjacent tissues demonstrated a positive 
signal (Fig. 3D).
Table 1.  Incidences of Thyroid Dysplasia and Proliferative Lesions in the DMBDD-treated Rats
Proliferative lesion
Total number of rats 114
Number of rats
Rats with thyroid dysplasia  
9 (7.9%)a
Rats without thyroid dysplasia  
105 (92.1%)
Follicular cell hyperplasia
   Number of rats 1 (11.1%) 6 (5.7%)
   Number of lesionsb 1 11
   Multiplicityc 1.0 1.8 ± 0.75d
Follicular cell adenoma
   Number of rats 5 (55.6%)* 7 (6.7%)
   Number of lesions 22 10
   Multiplicity 4.4 ± 5.5 1.4 ± 0.79
Follicular cell carcinoma
   Number of rats 0 (0.0%) 1 (1.0%)
   Number of lesions 0 1
   Multiplicity 0.0 1.0
* Significantly different from the incidence of adenomas of rats without thyroid dysplasia (P < 0.05). a Values in 
parentheses show incidences. b Number of proliferative lesions was counted from bilateral thyroid glands on one 
section. c Mean number of proliferative lesions per rat. d Mean ± SD.
Fig. 1.  Follicular cell hyperplasia in the DMBDD-treated rats with thyroid dysplasia (H.E. staining). The follicle is lined by a single layer 
of epithelial cells (A) with small vacuoles (arrowheads) (B).Dysplastic Thyroid Proliferative Lesions in GALAS Rats 14
Fig. 2.  Follicular cell adenomas in the DMBDD-treated rats with thyroid dysplasia (H.E. staining). The adenomas are observed as multiple nod-
ules, well demarcated and slightly compressing their adjacent tissue (A). They were principally lined by a single layer of epithelial cells 
(A, nodules f, g, h and i) and occasionally formed irregular papillary projections into the lumen (B, high magnification of nodule h). The 
follicular cells of adenomas are composed of a high columnar epithelium with huge vacuoles (C lower half, high magnification of nodule 
f), a low columnar epithelium with small vacuoles (D, high magnification of nodule g) or a basophilic epithelium without vacuoles (C 
upper half, high magnification of nodule h). The thyroid follicular cells in the adjacent tissue demonstrated thyroid dysplasia (E).Abe, Hayashi, Usuda et al. 15
Discussion
There are several reports regarding spontaneous thyroid 
proliferative lesions in GALAS rats with thyroid dysplasia. 
Weber et al. described that GALAS rats with normal growth 
but thyroid dysplasia did not exhibit higher incidences of 
preneoplastic or neoplastic changes in the thyroid gland in 
oncogenicity studies3. On the other hand, it has been shown 
that the incidence of thyroid tumor in dwarf rats with thy-
roid dysplasia is higher than that of normal GALAS rats5. In 
the dwarf rats, little colloid formation and a decreased fol-
licular size are observed in the thyroid, and the serum val-
ues of GH, T3 and T4 are markedly low3,4. The dwarf rats are 
thought to be affected by primary hypothyroidism, which 
induces the hypersecretion of thyroid stimulating hormone 
(TSH) from the anterior pituitary3,4. The persistent hyper-
secretion of TSH is involved in the increased incidence of 
thyroid and TSH-producing pituitary tumor5. In the present 
study, the incidence of adenoma in rats with thyroid dyspla-
sia was significantly greater than that of rats without thyroid 
dysplasia in the DMBDD-treated rats. Although the plasma 
hormone levels were not determined in this study, no hy-
Fig. 3.  PAS features (A) and immunostainings for thyroglobulin (B), T4 (C) and calcitonin (D) of follicular cell adenomas in the DMBDD-
treated rats with thyroid dysplasia. Nodules f, g and h are identical to those referred to in Fig. 2A.




Luminal colloid Follicular cells
PAS Thyroglobulin T4 PCNA
− ± + ++ − ± + ++ − ± + ++ − ± + ++
Rats with thyroid dysplasia 22 1 0 19 2 1 0 21 0 5 6 11 0 0 8 12 2
Rats without thyroid dysplasia 10 0 1 9 0 0 1 9 0 0 3 7 0 0 0 7 3
Grade signs −, ±, + and ++ represent none, minimal, slight and moderate, respectively. a Number of adenomas was counted from bilateral thyroid 
glands on one section.Dysplastic Thyroid Proliferative Lesions in GALAS Rats 16
pertrophy or proliferative lesions were observed in the pitu-
itary of rats both with and without thyroid dysplasia. From 
these observations, it appears that dysplastic thyroids of rats 
showing normal growth are more sensitive to carcinogens 
than normal thyroids, which is considered to be independent 
of the persistent TSH hypersecretion. Further studies will 
be needed to elucidate the mechanisms of high sensitivity 
to carcinogens in GALAS rats showing normal growth with 
thyroid dysplasia.
The adenomas induced by carcinogens in rats with 
thyroid dysplasia were composed of variously sized vacu-
olated cells or unvacuolated cells. These cellular morpho-
logical profiles may be just variation and attributable to the 
genetic background of GALAS rats with the intracellular 
vacuoles caused by the dilation of r-ERs. The materials of 
intracellular vacuoles react positively for thyroglobulin in 
the dwarfs of GALAS rats3,4. The cause of vacuolation was 
thought to be a mutation of the thyroglobulin gene resulting 
in retention of misfolded thyroglobulin in r-ERs similar to 
the mechanism described for the rdw rat, which developed 
dwarfism  by  genetic  hypothyroidism,  and  huge  vacuoles 
in the thyroid gland11. In contrast, the vacuoles of GALAS 
rats showing normal growth with thyroid dysplasia were not 
stained for thyroglobulin in the present study and other re-
ported works2,4. Thus, it is still not clear what was contained 
in the dilated r-ERs of GALAS rats showing normal growth 
with thyroid dysplasia. On the other hand, the histopatho-
logical features were fundamentally similar regardless of 
the presence or absence of thyroid dysplasia, except for the 
vacuoles.
The luminal colloids in most adenomas were positive 
for PAS and thyroglobulin in both animals with thyroid 
dysplasia and without thyroid dysplasia. The expression of 
thyroglobulin has been reported to disappear in a solid (mi-
crofollicular) histological pattern of thyroid follicular cell 
adenoma and carcinoma12. It has been considered that the 
tumors with a solid pattern indicate undifferentiated forms 
and may be unable to synthesize and store thyroglobulin 
protein12. Actually, the luminal colloid of a follicular cell 
carcinoma with a solid pattern, observed in a rat without 
thyroid dysplasia, was also negative for thyroglobulin in this 
study. From these findings, the positive expression of thy-
roglobulin in the neoplasms observed in the animals with 
thyroid dysplasia indicates that they are not undergoing 
malignant transformation. On the other hand, the luminal 
colloid in adenomas of rats with thyroid dysplasia showed a 
tendency to decrease in terms of the stainability of T4 when 
compared with that of rats without thyroid dysplasia. Few 
reports have appeared in the literature on the relationships 
between T4 and follicular cell tumor. It is unclear why ad-
enomas in rats with thyroid dysplasia have such a tendency, 
but it might be associated with the genetic background.
In conclusion, we evaluated incidences of thyroid 
proliferative lesions with or without thyroid dysplasia in 
our medium-term carcinogenicity study and observed the 
morphological features of these lesions. It appears that dys-
plastic thyroids of rats showing normal growth are more 
sensitive to carcinogens than normal thyroids. In addition, 
the morphological features of carcinogen-induced thyroid 
proliferative lesions in GALAS rats with thyroid dysplasia 
were fundamentally similar to those of rats without thyroid 
dysplasia, except for the vacuoles and T4 staining profile.
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